Connect2Care prostate cancer education and screening support for African American men
Official title: Connect2Care: A Randomized Clinical Trial of a Smartphone-based Application for Prostate Cancer Education and Screenings for African American Men
Run by University of Oklahoma · NCT07055165 · Data updated 2026-11-12
This 30-day test will see if the Connect2Care app can improve prostate cancer knowledge and increase readiness to get a PSA test among African American men aged 45–69 in Oklahoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 69 Years |
| Sex | Men only |
| Enrollment | 466 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Status | Recruiting |
| Started | July 26, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | September 25, 2025 |
| Trial ID | NCT07055165 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Black/African American men aged 45–69 who live in Oklahoma, are not currently diagnosed with prostate cancer, are not up to date with PSA screening, and are willing to use a phone app for 30 days.
✕Probably not a fit
Men already up to date with PSA screening, those diagnosed with prostate cancer, or anyone unwilling to use a smartphone app are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, 1:1, 30-day trial will assign 266 African American men in Oklahoma who are not up to date with PSA screening to use either the Connect2Care app or the U.S. Prevention Taskforce app. The study measures post-intervention differences in prostate cancer knowledge, perceived benefits and risks of screening, and readiness to complete a PSA test using validated self-report questionnaires. App engagement and accessibility will be tracked via self-report measures, and acceptability will be explored through semi-structured qualitative interviews. The trial will also analyze predictors of screening readiness across both arms.
Why it matters
Potential benefit: If successful, the app could increase knowledge and motivation to pursue appropriate PSA screening, potentially enabling earlier detection of prostate cancer in this population.
How similar studies have gone: Some prior digital education and decision-aid interventions have improved prostate cancer knowledge and screening intentions, but there are limited rigorous RCT data specifically focused on African American men.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Live in Oklahoma * Self-identify as Black/African American * Self-identify as male * Between ages 45-69 * Not currently diagnosed with prostate cancer Exclusion Criteria: * Participants will be excluded if they are not interested in using a phone app for 30 days * Has taken a PSA test or has completed PSA screening within the past two years
Where it's running
-
TSET Health Promotion Research Center
Oklahoma City, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Jordan Neil, PhD — University of Oklahoma
- Study coordinator: Jordan Neil, PhD
- Email: jordan-neil@ouhsc.edu
- Phone: (405) 271-5046
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Sleep Better, Live Better: a 12-week coaching program to help adults improve sleep and heart-brain health
This trial tests a 12-week, telephone- and text-based sleep coaching program for adults 25–65 with short sleep and higher cardiometabolic risk to see if it improves sleep and related behaviors.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.